[go: up one dir, main page]

CN1429118A - 芳香酶抑制剂和单克隆抗her2抗体作为抗肿瘤剂 - Google Patents

芳香酶抑制剂和单克隆抗her2抗体作为抗肿瘤剂 Download PDF

Info

Publication number
CN1429118A
CN1429118A CN01809581A CN01809581A CN1429118A CN 1429118 A CN1429118 A CN 1429118A CN 01809581 A CN01809581 A CN 01809581A CN 01809581 A CN01809581 A CN 01809581A CN 1429118 A CN1429118 A CN 1429118A
Authority
CN
China
Prior art keywords
her2
aromatase inhibitor
antibody
exemestane
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01809581A
Other languages
English (en)
Chinese (zh)
Inventor
G·马斯米尼
G·皮斯特里
D·普兰达尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn SpA
Pharmacia and Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn SpA, Pharmacia and Upjohn Co filed Critical Pharmacia and Upjohn SpA
Publication of CN1429118A publication Critical patent/CN1429118A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN01809581A 2000-05-15 2001-04-19 芳香酶抑制剂和单克隆抗her2抗体作为抗肿瘤剂 Pending CN1429118A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57135500A 2000-05-15 2000-05-15
US09/571,355 2000-05-15

Publications (1)

Publication Number Publication Date
CN1429118A true CN1429118A (zh) 2003-07-09

Family

ID=24283360

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01809581A Pending CN1429118A (zh) 2000-05-15 2001-04-19 芳香酶抑制剂和单克隆抗her2抗体作为抗肿瘤剂

Country Status (20)

Country Link
EP (1) EP1282440A1 (xx)
JP (1) JP2003533490A (xx)
KR (1) KR20030014223A (xx)
CN (1) CN1429118A (xx)
AU (1) AU784617B2 (xx)
BR (1) BR0110732A (xx)
CA (1) CA2409652A1 (xx)
CZ (1) CZ20023748A3 (xx)
EA (1) EA005931B1 (xx)
EE (1) EE200200622A (xx)
HK (1) HK1054200A1 (xx)
HU (1) HUP0301877A2 (xx)
IL (1) IL152389A0 (xx)
MX (1) MXPA02011194A (xx)
NO (1) NO20025302D0 (xx)
NZ (1) NZ523004A (xx)
PL (1) PL360153A1 (xx)
SK (1) SK16022002A3 (xx)
WO (1) WO2001087334A1 (xx)
ZA (1) ZA200209815B (xx)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101014365B (zh) * 2004-07-16 2011-04-13 辉瑞产品公司 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
CN102068429A (zh) * 2010-12-28 2011-05-25 西南大学 法倔唑在诱导罗非鱼已分化卵巢转变为功能型精巢中的应用及其诱导方法

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
EP1282443B1 (en) 2000-05-19 2009-09-02 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
ES2269682T3 (es) * 2001-01-26 2007-04-01 Pfizer Italia S.R.L. Exemestano para tratar transtornos que dependen de hormonas.
GB2375958B (en) 2001-04-09 2005-03-02 George Margetts The use of steroids to lower the levels of cortisol
AU2003218600C1 (en) 2002-03-26 2009-12-17 Zensun (Shanghai) Science & Technology Co., Ltd. ERBB3 based methods and compositions for treating neoplasms
CN1678348A (zh) * 2002-07-01 2005-10-05 萨文特医药公司 用于治疗性治疗的组合物和方法
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
UA94899C2 (ru) 2005-01-21 2011-06-25 Дженентек, Инк. Фиксированное дозирование антител к her
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
EP1945224B1 (en) 2005-10-19 2012-05-02 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
EP2132573B1 (en) 2007-03-02 2014-04-23 Genentech, Inc. Predicting response to a her dimerisation inhbitor based on low her3 expression
DK2171090T3 (da) 2007-06-08 2013-06-10 Genentech Inc Genekspressionsmarkører for tumorresistens over for HER2-inhibitorbehandling
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
ES2572728T3 (es) 2009-03-20 2016-06-02 F. Hoffmann-La Roche Ag Anticuerpos anti-HER biespecíficos
CA2761280A1 (en) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
CN102892779B (zh) 2010-02-18 2016-12-21 基因泰克公司 神经调节蛋白拮抗剂及其在治疗癌症中的用途
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
MX2014001766A (es) 2011-08-17 2014-05-01 Genentech Inc Anticuerpos de neuregulina y sus usos.
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
CN106987620A (zh) 2011-11-30 2017-07-28 霍夫曼-拉罗奇有限公司 癌症中的erbb3突变
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
JP2015514710A (ja) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Ｈｅｒ３阻害剤に関する診断及び治療
US20160038490A1 (en) * 2012-07-18 2016-02-11 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases
WO2014083178A1 (en) 2012-11-30 2014-06-05 F. Hoffmann-La Roche Ag Identification of patients in need of pd-l1 inhibitor cotherapy
US10064874B2 (en) 2014-10-22 2018-09-04 Havah Therapeutics Pty Ltd. Methods of reducing mammographic breast density and/or breast cancer risk
AU2016343297A1 (en) 2015-10-22 2018-05-10 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
CN107417791B (zh) * 2017-08-17 2020-09-22 合肥瀚科迈博生物技术有限公司 抗人ErbB2双特异性抗体、其制备方法及用途
CN119970752A (zh) 2019-06-03 2025-05-13 哈瓦赫治疗有限公司 用于递送雄激素剂和芳香酶抑制剂的药物制剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101014365B (zh) * 2004-07-16 2011-04-13 辉瑞产品公司 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
CN102068429A (zh) * 2010-12-28 2011-05-25 西南大学 法倔唑在诱导罗非鱼已分化卵巢转变为功能型精巢中的应用及其诱导方法

Also Published As

Publication number Publication date
SK16022002A3 (sk) 2003-04-01
NO20025302L (no) 2002-11-05
HUP0301877A2 (hu) 2003-09-29
CZ20023748A3 (cs) 2003-04-16
EA200201213A1 (ru) 2003-04-24
AU5630901A (en) 2001-11-26
PL360153A1 (en) 2004-09-06
ZA200209815B (en) 2003-12-03
WO2001087334A1 (en) 2001-11-22
EP1282440A1 (en) 2003-02-12
EA005931B1 (ru) 2005-08-25
KR20030014223A (ko) 2003-02-15
JP2003533490A (ja) 2003-11-11
BR0110732A (pt) 2003-02-04
AU784617B2 (en) 2006-05-18
HK1054200A1 (zh) 2003-11-21
EE200200622A (et) 2004-06-15
NZ523004A (en) 2004-09-24
CA2409652A1 (en) 2001-11-22
MXPA02011194A (es) 2003-03-10
NO20025302D0 (no) 2002-11-05
IL152389A0 (en) 2003-05-29

Similar Documents

Publication Publication Date Title
CN1429118A (zh) 芳香酶抑制剂和单克隆抗her2抗体作为抗肿瘤剂
AU2001239913B2 (en) Method of treating cancer with anti-neurotrophin agents
US20050032759A1 (en) Antitumor combined therapy
AU2012229147B2 (en) Use of inhibitors of EGFR-family receptors in the treatment of hormone refractory breast cancers
US20120294873A1 (en) ANTI-EpCAM IMMUNOGLOBULINS
IL295098B2 (en) Combinations of trastuzumab-mcc-dm1 and 5-fu for use in treatment of a cancer expressing erbb2
TW201536319A (zh) 抗腫瘤劑及抗腫瘤效果增強劑
JP2023085422A (ja) 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
EP3449939B1 (en) Pharmaceutical composition for inhibiting metastasis of cancer, comprising, as active ingredient, antibody that specifically binds to epidermal growth factor receptor
WO2024213081A1 (zh) 抗体药物偶联物在制备预防和/或治疗癌症的药物中的用途
CN121513160A (zh) 梭杆菌特异性抗菌肽在制备促进抗肿瘤免疫治疗功效的药物中的应用
JPWO2022033978A5 (xx)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1054200

Country of ref document: HK